ALKERMES | ALKS - Operating Expenses


ALKERMES reported $1.73B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 10.72B 1.28B Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Otsuka Holdings JPY 469.16B 21.76B Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025